logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12617783 B1

PDFFull Text
Date of Patent:
May. 05, 2026

Filed:

Mar. 28, 2025

Heterocyclic glp-1r agonists

Applicant:

Biomea Fusion, Inc., Redwood City, CA (US);

Inventors:

Xiaodong Wang, Millbrae, CA (US);

Thorsten A. Kirschberg, San Carlos, CA (US);

Johannes H. Voigt, San Carlos, CA (US);

Thomas Butler, Redwood City, CA (US);

Ravindra B. Upasani, San Jose, CA (US);

Yongli Su, Foster City, CA (US);

Thu Phan, Fremont, CA (US);

James T. Palmer, Warrandyte, AU;

Neil Howard Squires, San Francisco, CA (US);

Yeyu Cao, Foster City, CA (US);

Solomon B. Ungashe, Sunnyvale, CA (US);

Nan-Horng Lin, Vernon Hills, IL (US);

Mini Balakrishnan, San Mateo, CA (US);

Petr Jansa, Foster City, CA (US);

Satish Goud Pappali, Sunnyvale, CA (US);

Assignee:

BIOMEA FUSION, INC., Redwood City, CA (US);

Attorney:

SQUIRE PATTON BOGGS (US)

Primary Examiner:

Jeffrey S Lundgren

Assistant Examiner:

Eric undefined Tran

Int. Cl.
CPC ...
C07D 451/00 (2006.01); A61K 31/437 (2006.01); A61K 31/439 (2006.01); A61K 31/46 (2006.01); A61K 31/4709 (2006.01); A61K 31/496 (2006.01); A61K 31/502 (2006.01); A61K 31/5377 (2006.01); A61K 31/5386 (2006.01); A61K 31/541 (2006.01); A61K 31/55 (2006.01); A61K 31/551 (2006.01); A61K 31/675 (2006.01); C07D 471/04 (2006.01); C07D 471/18 (2006.01); C07D 487/04 (2006.01); C07D 498/18 (2006.01); C07D 519/00 (2006.01); C07F 9/6561 (2006.01);
U.S. Cl.
CPC ...
C07D 451/00 (2013.01); A61K 31/437 (2013.01); A61K 31/439 (2013.01); A61K 31/46 (2013.01); A61K 31/4709 (2013.01); A61K 31/496 (2013.01); A61K 31/502 (2013.01); A61K 31/5377 (2013.01); A61K 31/5386 (2013.01); A61K 31/541 (2013.01); A61K 31/55 (2013.01); A61K 31/551 (2013.01); A61K 31/675 (2013.01); C07D 471/04 (2013.01); C07D 471/18 (2013.01); C07D 487/04 (2013.01); C07D 498/18 (2013.01); C07D 519/00 (2013.01); C07F 9/6561 (2013.01);
Abstract

Disclosed herein are heterocyclic compounds that activate GLP-1R pathways. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the GLP-1R agonists are disclosed, alone or in combination with other therapeutic agents, for the treatment of diabetes, obesity, and other diseases or conditions dependent on GLP-1R pathways.

Find Patent Forward Citations

Loading…